Last reviewed · How we verify
Gemifloxacin-based triple therapy
Gemifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.
Gemifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria. Used for Community-acquired bacterial respiratory tract infections (as part of triple therapy).
At a glance
| Generic name | Gemifloxacin-based triple therapy |
|---|---|
| Also known as | Factive, Rabiet, Pamoxin |
| Sponsor | Samsung Medical Center |
| Drug class | Fluoroquinolone antibiotic |
| Target | Bacterial DNA gyrase and topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
As a fluoroquinolone, gemifloxacin works by binding to and inhibiting bacterial DNA gyrase and topoisomerase IV enzymes, which are essential for bacterial DNA replication, transcription, and repair. When used as part of a triple therapy regimen, gemifloxacin is combined with other antimicrobial agents to enhance efficacy and reduce resistance development. This combination approach is typically employed in treating respiratory tract infections or other serious bacterial infections.
Approved indications
- Community-acquired bacterial respiratory tract infections (as part of triple therapy)
Common side effects
- Nausea
- Diarrhea
- Headache
- Tendinopathy
- QT prolongation
Key clinical trials
- Randomized Study on Efficacy of Gemifloxacin-based Regimen for Helicobacter Pylori Infection (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gemifloxacin-based triple therapy CI brief — competitive landscape report
- Gemifloxacin-based triple therapy updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI